Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 3/2004

01.09.2004 | Original Article

Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children

verfasst von: Marshall P. Goren, Sidnei Epelman, Dorothy A. Bush

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2004

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To describe mesna excretion in children.

Patients and methods

We studied 14 children (aged 1–18 years) who received 1.8 g/m2 of ifosfamide per day for 5 days. For uroprotection, the children were given intravenous mesna (equal to 20% of the ifosfamide dose) followed by two oral doses (each equal to 40% of the ifosfamide dose). The concentrations of mesna and the metabolite dimesna were measured in urine samples collected on treatment days 1 and 5.

Results

Of 14 patients enrolled, 11 (aged 4–18 years) were evaluable. The profiles of mesna excretion rates were similar on days 1 and 5. Mesna excretion declined rapidly over 1–2 h after intravenous dosing. Increases in mesna excretion after oral dosing lagged by 2–4 h. About 21% of the mesna administered was excreted unchanged over 24 h on both days 1 and 5. The proportion excreted varied by severalfold between patients, but there was no association with age.

Conclusion

The profile of mesna excretion after intravenous and oral dosing in these children was similar to that in reported studies of ifosfamide-treated adults.
Literatur
1.
Zurück zum Zitat Brock N, Pohl J, Stekar J, Scheef W (1982) Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention-III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 18:1377 Brock N, Pohl J, Stekar J, Scheef W (1982) Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention-III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 18:1377
2.
Zurück zum Zitat Cohen MH, Dagher R, Griebel DJ, Ibrahim A, Martin A, Scher NS, Sokol GH, Williams GA, Pazdur R (2002) U.S. Food and drug administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist 7:393PubMed Cohen MH, Dagher R, Griebel DJ, Ibrahim A, Martin A, Scher NS, Sokol GH, Williams GA, Pazdur R (2002) U.S. Food and drug administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist 7:393PubMed
3.
Zurück zum Zitat Fukuoka M, Negoro S, Masuda N, Furuse K, Kawahara M, Kodama N, Ikegami H, Nakamura S, Nishio H, Ohnoshi T (1991) Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 117:473PubMed Fukuoka M, Negoro S, Masuda N, Furuse K, Kawahara M, Kodama N, Ikegami H, Nakamura S, Nishio H, Ohnoshi T (1991) Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 117:473PubMed
4.
Zurück zum Zitat Goren MP, Lyman BA, Li JT (1991) The stability of mesna in beverages and syrup for oral administration. Cancer Chemother Pharmacol 28:298PubMed Goren MP, Lyman BA, Li JT (1991) The stability of mesna in beverages and syrup for oral administration. Cancer Chemother Pharmacol 28:298PubMed
5.
Zurück zum Zitat Goren MP, Anthony LB, Hande KR, Johnson DH, Brade WP, Frazier MW, Bush DA, Li JT (1998) Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide. J Clin Oncol 16:616PubMed Goren MP, Anthony LB, Hande KR, Johnson DH, Brade WP, Frazier MW, Bush DA, Li JT (1998) Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide. J Clin Oncol 16:616PubMed
6.
Zurück zum Zitat Goren MP, Houle JM, Bush DA (1998) Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects. Clin Cancer Res 4:2313PubMed Goren MP, Houle JM, Bush DA (1998) Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects. Clin Cancer Res 4:2313PubMed
7.
Zurück zum Zitat Mace JR, Keohan ML, Bernardy H, Junge K, Niebch G, Romeis P, Thoma A, Wagner T, Mueller U, Demetri G, Baker LH (2003) Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. Clin Cancer Res 9:5829PubMed Mace JR, Keohan ML, Bernardy H, Junge K, Niebch G, Romeis P, Thoma A, Wagner T, Mueller U, Demetri G, Baker LH (2003) Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. Clin Cancer Res 9:5829PubMed
8.
Zurück zum Zitat Schuchter LM, Hensley ML, Meropol NJ, Winer EP (2002) 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20:2895CrossRefPubMed Schuchter LM, Hensley ML, Meropol NJ, Winer EP (2002) 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20:2895CrossRefPubMed
Metadaten
Titel
Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children
verfasst von
Marshall P. Goren
Sidnei Epelman
Dorothy A. Bush
Publikationsdatum
01.09.2004
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 3/2004
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-004-0801-6

Weitere Artikel der Ausgabe 3/2004

Cancer Chemotherapy and Pharmacology 3/2004 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.